echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > The 2020 edition of the CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer has four bright spots in the first-line treatment pattern.

    The 2020 edition of the CSCO Guidelines for the Diagnosis and Treatment of Primary Liver Cancer has four bright spots in the first-line treatment pattern.

    • Last Update: 2020-09-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, the Chinese Society of Clinical Oncology (CSCO) officially released the high-profile 2020 edition of the Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (hereinafter referred to as the Guidelines).
    In the new edition of the Guide, the first-line treatment pattern of advanced hepatocellular carcinoma (HCC) has changed significantly, with targeted therapies, immunotherapy and combination therapies becoming the main themes, while a number of new drugs from Ze-Yuan Pharmaceuticals and Hengrui Pharmaceuticals have attracted much attention.
    this article to filter out some of the highlights of the new edition of the Guide for readers only.
    late HCC first-line treatment recommended highlights one: China's domestic small molecule new drug was recommended grade I Donaphini is zealo pharmaceutical independent research and development of oral multi-target, multi-kinase inhibitor-type small molecule anti-tumor drugs, belongs to class 1 new drugs.
    new edition of the Guidelines lists it as a first-line treatment for advanced hepatocellular carcinoma and is recommended by A-level experts (category 1A evidence).
    that this is the first time that China's domestic small molecule targeted drugs have been CSCO guidelineSCO HCC first-line treatment I-level recommendation.
    recommendation is based on the results of a multi-center Phase 2/3 clinical trial called ZGDH3.
    ZGDH3 study, designed and organized independently by Professors Qin Shuxuan and Bi Feng, included 668 HCC patients in China, and is one of the largest clinical studies of liver cancer in Chinese samples to date.
    results show that Donafine significantly extends the total survival of patients with advanced HCC (12.1 months vs 10.3 months) compared to sorafini and has better safety and tolerance.
    result represents a major breakthrough in the field of liver cancer treatment with innovative drugs made in China.
    , Donaphini has submitted a listing application in China for the treatment of patients with hepatocellular carcinoma.
    Highlight II: I-level recommendation of the addition of atili-pearl monoantigen and beva-pearl monoimmune combination therapy In the new version of the Guidelines, the late HCC first-line treatment also added another level I expert recommendation (class I evidence) - atili-pearl monoantigen and beval-pearl monoimmune combination therapy (T-A).
    fact, this combination therapy has previously been listed as a first-line recommendation for liver cancer by NCCN, ESMO and other internationally renowned guidelines, and was approved by the FDA in May this year for first-line treatment of hepatocellular carcinoma.
    atezolizumab is Roche's PD-L1 inhibitor, and Beva's bead monoantitor is an endovascular enditer growth factor (VEGF) inhibitor.
    Based on a multi-center Phase 3 clinical study called IMbrave 150, 501 subjects were randomly assigned to the T-A and Solafini single-drug treatment groups at 2:1 for non-removable HCC patients who had not previously received systematic treatment.
    results showed that the combined treatment of atili-pearl monoantigen and beva-pearl monoimmune improved patient OS (not up to vs 13.2 months), PFS (6.8 months vs 4.3 months) and ORR (27% vs 12%), reducing the risk of death by 42%.
    positive results provide strong evidence of the benefits of immunologic co-treatment in terminal HCC patients worldwide, including in China.
    Highlight III: Hengrui Pharmaceutical PD-1 and Small Molecule Targeting Drug Double Harvest In the new edition of the Guide, PD-1 antibody Karelli Pearl Monoanti and Small Molecule Multi-Target Anti-Angiogenic Oral Drug Apatinist developed by Hengrui Pharmaceuticals are included.
    among them, Osali platinum-based system chemotherapy combined with carelli pearl monoanti, and apatinib combined carelli pearl monoanti, were recommended by advanced HCC first-line therapy III.class experts (class 2B evidence).
    it is worth mentioning that Karelli Zhudant has been approved for liver cancer adaptation in China in March this year.
    based on a single-arm, multi-center Phase 2 clinical trial led by Professor Qin Shuxuan as the lead researcher (PI) for the first-line treatment of liver cancer with Karelli-Zhu single-drug combination chemotherapy.
    study included 34 patients with advanced HCC who had not received systematic treatment, and treated the classic chemotherapy treatment with a combination of carelli's monoantigen and oxalipal.
    results showed that the combined therapy confirmed ORR of 26.5%, DCR of 79.4%, and the medium PFS of 5.5 months.
    it is learned that the carelliju single anti-combination FOLFOX4 system chemotherapy as a first-line treatment of late HCC randomized, multi-center phase 3 clinical studies are being carried out.
    addition, according to a 1b study previously published in the Journal of Clinical Oncology, the first-line treatment of advanced hepatocellular carcinoma was significant.
    , ORR was as high as 50%, the medium disease-free progressity lifetime (mPFS) was 7.2 months, and the six-week disease control rate was 93.8%.
    it is learned that the third phase of clinical research on the first-line treatment of advanced hepatocellular carcinoma by Karelliju single anti-combined apatinist has been carried out simultaneously in more than 10 countries and regions in the United States, Russia, China and more than 100 centers.
    Highlight IV: Level III recommends the addition of two new PD-1 antibodies in the new edition of the Guide, Eisai's oral polymember tyrosine kinase inhibitor Lenvima combined with Pabli pearl monoanti or Navuliyu monoantitor obtained late HCC first-line treatment CLASS III.class expert recommendation (class 2B evidence).
    based on data released at this year's ANNUAL MEETING of ASCO, the combined treatment of mercaton (MSD) PD-1 antibody Paboliju monoantigen and lenforatinib achieved a clinically significant total remission rate for non-removable HCC patients who did not receive systematic treatment.
    this is an open-label, one-arm Phase 1b clinical trial called KEYNOTE-524/study116, which showed that combination therapy reached 36% ORR and the medium DOR reached 12.6 months.
    PD-1 combination therapy of lenphatinis has also made good progress in the first-line treatment of liver cancer.
    , based on data released this year at this year's American Society of Clinical Oncology Gastrointestinal Oncology Symposium (2020 ASCO GI), in a Phase 1b clinical study called Study117, Lenphatini combined with BMS P D-1 antibody Navuliyu monoantigen therapy non-excisible HCC, ORR reached 76.7%, DCR 96.7%, clinical benefit rate (CBR) was 83.3%, complete remission (CR) was 10%.
    also suggests that the lenvatinib combined with Navuliyu monoanti is expected to bring new hope to patients with advanced liver cancer.
    is a cancer with limited treatment options and a high degree of aggression, and is one of the leading causes of cancer death worldwide.
    statistics, there are about 370,000 new cases of hepatocellular carcinoma in China every year, and about 85% of Chinese patients have missed the best time to treat them because of the low rate of early screening.
    patients with a medium survival of only about 10 months and a five-year survival rate of only about 12%.
    , the emergence of innovative therapies has brought many new options to patients with advanced liver cancer.
    new edition of the Guidelines includes the latest treatments of the day, providing doctors and patients with strong drug support.
    we look forward to more breakthroughs in this area that will bring more benefits to patients with liver cancer.
    References to The inclusion of Donaphini in CSCO's Guidelines for the Diagnosis and Treatment of Primary Liver Cancer was recommended by I. level experts. Retrieved Jul 3,2020, from Zee-Yuan Pharmaceuticals Website s2. Henrui PD-1 Treatment of Chinese Liver Cancer Data published in The Lancet Oncology. Retrieved Feb 8,2020, from Hengrui Pharmaceuticals website , CSCO authoritative guidelines issued . . . China's liver cancer treatment ushered in a new dawn, the epoch-making treatment pattern is coming. Retrieved Jul 20, 2020, from CSCO.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.